M
Mohamad Mohty
Researcher at University of Paris
Publications - 984
Citations - 26661
Mohamad Mohty is an academic researcher from University of Paris. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 69, co-authored 801 publications receiving 19109 citations. Previous affiliations of Mohamad Mohty include Pierre-and-Marie-Curie University & University of Nantes.
Papers
More filters
Journal ArticleDOI
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
Jean-Luc Harousseau,Michel Attal,Hervé Avet-Loiseau,Gerald Marit,Denis Caillot,Mohamad Mohty,Pascal Lenain,Cyrille Hulin,Thierry Facon,Philippe Casassus,Mauricette Michallet,Hervé Maisonneuve,Lotfi Benboubker,Frédéric Maloisel,Marie-Odile Petillon,Iain J. Webb,Claire Mathiot,Philippe Moreau +17 more
TL;DR: Bortezomib plus dexamethasone significantly improved postinduction and post-transplantation CR/nCR and at least VGPR rates compared with VAD and resulted in a trend for longer PFS and should be considered a standard of care in this setting.
Journal ArticleDOI
Mechanisms of action of antithymocyte globulin : T-cell depletion and beyond
TL;DR: ATG provides multifaceted immunomodulation paving the way for future applications and suggesting that the use of ATG should be included in the immunosuppression therapeutic armamentarium to help reduce the incidence of organ rejection and GVHD.
Journal ArticleDOI
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser,Nikolas von Bubnoff,Jason Butler,Mohamad Mohty,Dietger Niederwieser,Reuven Or,Jeff Szer,Eva Maria Wagner,Tsila Zuckerman,Bruyère Mahuzier,Judith Xu,Celine Wilke,Kunal K. Gandhi,Gérard Socié +13 more
TL;DR: Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy.
Journal ArticleDOI
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
Jan J. Cornelissen,Alois Gratwohl,Richard F. Schlenk,Jorge Sierra,Martin Bornhäuser,Gunnar Juliusson,Zdenek Racil,Jacob M. Rowe,Nigel H. Russell,Mohamad Mohty,Bob Löwenberg,Gerard Socie,Dietger Niederwieser,Gert J. Ossenkoppele +13 more
TL;DR: It is suggested that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment, and the approach requires initial disease risk Assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors.
Journal ArticleDOI
Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories
Régis Peffault de Latour,Jean Yves Mary,Celia Salanoubat,Louis Terriou,Gabriel Etienne,Mohamad Mohty,Sophie Roth,Sophie de Guibert,Sébastien Maury,Jean-Yves Cahn,Gérard Socié +10 more
TL;DR: Although clinical presentation and prognosis factors are different, classic PNH and AA-PNH syndrome present roughly similar outcomes, affected mainly by complications.